In May, the Cure JM Clinical Care Network was pleased to invite juvenile dermatomyositis healthcare professionals to join us virtually for the latest presentations from world-leading researchers and clinicians on advancements in basic research, translational studies, and best-practice clinical care in juvenile dermatomyositis.
Este acto incluyó sesiones sobre diversos temas, con el objetivo principal de mejorar la experiencia global de pacientes y proveedores mediante la colaboración y el intercambio de mejores prácticas.
Destinatarios:
- Cualquier clínico o investigador interesado en la investigación o atención de las IIM
- Reumatólogos, dermatólogos e inmunólogos pediátricos y de adultos
- Residentes y becarios
- Profesores dermatomiositis, polimiositis y campos de estudio relacionados
- HCP que tratan enfermedades autoinmunes en adultos o jóvenes
- Representantes del sector
Nos complace compartir a continuación cada una de las presentaciones y los resultados de cada sesión:
Sesión científica (3,0 créditos CME disponibles a través de la Universidad de Duke)
Recommendations for the Treat-to-Target Strategy in JDM
About Dr. Ravelli:
Angelo Ravelli, MD, is Scientific Director of the Giannina Gaslini Institute of Genoa, Italy and Professor of Pediatrics at the University of Genoa, Italy. He is past President of the Pediatric Rheumatology European Society (PReS) and Editor-in-Chief of Pediatric Rheumatology.
Dr. Ravelli has recently been co-chair of the International Task Force that developed the recommendations for the treat-to-target strategy in juvenile dermatomyositis. He is author or co-author of more than 500 peer-reviewed articles and on Scopus he has more than 28.000 citations and an H index of 89.
A Deep Dive in Myositis Specific Antibodies and Juvenile Myositis
About Dr. Mammen:
After obtaining his M.D. and Ph.D. at Johns Hopkins, Dr. Mammen completed his neurology residency and neuromuscular fellowship at the same institution. He co-founded the Johns Hopkins Myositis Center in 2007, where he and his colleagues discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In 2014, Dr. Mammen moved to the NIH, where he is an Investigator and Leader of the Muscle Disease Unit.
In addition to seeing myositis patients at the NIH Clinical Center, he maintains an appointment as Adjunct Professor of Neurology and Medicine at Johns Hopkins, where he continues to see patients at the Myositis Center.
Pragmatic Clinical Trial Design in Pediatric Autoimmune Diseases
About Dr. Weiss:
Pamela Weiss, MD MSCE is an academic pediatric rheumatologist with advanced training in clinical epidemiology and a focus on the pharmacoepidemiology and outcomes of children with spondyloarthritis (SpA). She has developed disease response and outcome measures for youth with SpA as well as classification criteria for axial disease in juvenile SpA.
Dr. Weiss has over fifteen years of experience leading clinical research endeavors, including multi-center research and research involving international collaborations. Dr. Weiss has served on Steering Committees, Advisory Boards, and Data Monitoring Committees for pediatric trials.
Child and Caregiver Behavioral Health Screening Among Patients with Juvenile Dermatomyositis and Systemic Lupus Erythematosus
About Dr. Turnier:
Dr. Turnier is a Licensed Psychologist with the Department of Pediatrics, Division of Pediatric Psychology at the University of Michigan Health System. He works within the Integrated Behavioral Health program and specializes in the delivery of brief, problem-focused behavior interventions for a myriad of behavioral health concerns.
Dr. Turnier also works in two multidisciplinary clinics in collaboration with the Division of Rheumatology, specializing in the assessment and treatment of mental/behavioral health issues among patients diagnosed with a chronic rheumatic illness. He is actively involved in research, quality improvement initiatives, and program development.
Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis
About Sean Koester:
Sean Koester is presenting the findings of his sixth published research project. Mr. Koester currently serves as a research assistant for Dr. Neelendu Dey in the Fred Hutchinson Cancer Center where he’s filled various research roles over the past six years.
Presentación especial por invitación
About Lisa Rider:
Dr. Rider oversees investigators and trainees in the group and leads national and international consortia that evaluate and conduct a wide range of basic and clinical studies on juvenile and adult myositis. She obtained her M.D. at the Duke University School of Medicine, completed her pediatrics training at Seattle Children’s Hospital of University of Washington, and her fellowship in pediatric rheumatology at Seattle Children’s Hospital, Seattle, WA, Children’s National Medical Center, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.
Dr. Rider has focused much of her work on autoimmune muscle diseases in children and has received several awards of distinction. She has authored or co-authored nearly 200 research publications, reviews, books, and book chapters. She also co-established and is co-chair of the International Myositis Assessment and Clinical Studies Group (IMACS) and the Childhood Myositis Heterogeneity Study Group. Rider is vice chair of the Myositis Genetics Consortium (MYOGEN), which is leading studies to define new genetic risk and protective factors for myositis.
